Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

IMVT

Immunovant, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1764013Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2026
—
Net Income FY2026
$(506.0M)
EPS (Basic, as reported)
$-2.77
Net Margin FY2026
—
ROE FY2026
-59.3%
Total Equity
$853.0M
Shares Out
207M
Business description

Immunovant, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2026; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itNet income: (29) → (506)
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Research & development(26)(48)(69)(102)————
General & administrative(3)(18)(40)(54)(48)(57)(77)(76)
Total operating expenses(28)(66)(108)(156)(218)(283)(438)(533)
Interest expense—(1)0—————
Other income (expense), net000(1)0(1)02
Pre-tax income(29)(66)(108)(157)(211)(259)(413)(505)
Income tax expense00000(1)(1)0
Net income(29)(66)(107)(157)(211)(259)(414)(506)
EPS — basic——($1.22)($1.43)($1.71)($1.88)($2.73)($2.77)
EPS — diluted——($1.22)($1.43)($1.71)($1.88)($2.73)($2.77)
Shares outstanding — basic (M)——88110123138152182
Shares outstanding — diluted (M)——88110123138152182

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.